-

AbCellera to Participate at Upcoming Investor Conferences in September

VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) today announced that the Company will participate in the following investor conferences:

  • Wells Fargo Healthcare Conference, September 3-5, 2025
  • Morgan Stanley Annual Global Healthcare Conference, September 8-10, 2025

Visit AbCellera's Investor Relations website for additional information.

About AbCellera Biologics Inc.

AbCellera (Nasdaq: ABCL) is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines in the areas of endocrinology, women's health, immunology, and oncology. For more information, please visit www.abcellera.com.

Contacts

Inquiries
Media: Tiffany Chiu; media@abcellera.com, +1(236)521-6774
Partnering: Murray McCutcheon, Ph.D.; partnering@abcellera.com, +1(604)559-9005
Investor Relations: Peter Ahn; ir@abcellera.com, +1(778)729-9116

Industry:

AbCellera Biologics Inc.

NASDAQ:ABCL
Release Summary
AbCellera to Participate at Upcoming Investor Conferences in September
Release Versions
English
$Cashtags
$ABCL

Contacts

Inquiries
Media: Tiffany Chiu; media@abcellera.com, +1(236)521-6774
Partnering: Murray McCutcheon, Ph.D.; partnering@abcellera.com, +1(604)559-9005
Investor Relations: Peter Ahn; ir@abcellera.com, +1(778)729-9116

Social Media Profiles
AbCellera on LinkedIn
AbCellera on Twitter
More News From AbCellera Biologics Inc.

AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer...

AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575

VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575...

AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms

VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera Reports Q2 2025 Business Results & Initiation of a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms...
Back to Newsroom